Clinical Trial

Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This clinical trial consists of Phase I and Phase II. The objective is to evaluate the safety and immunogenicity of the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) in individuals aged 2 months (minimum 6 weeks) and older.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-06
Trial Details
NCT Number NCT07600983
Lead Sponsor CanSino Biologics Inc.
Conditions Streptococcus Pneumoniae Infection
Enrollment 854 participants
Start Date 2026-05-24
Primary Completion 2026-11-24 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-05